Skip to main content
Premium Trial:

Request an Annual Quote

Underwriters Exercise Over-allotment Option on Cancer Genetics IPO

NEW YORK (GenomeWeb News) – Cancer Genetics said after the close of the market on Friday that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase 90,000 additional shares of its stock at $10 per share.

As a result, the total gross proceeds from the offering are expected to be $6.9 million, Cancer Genetics said.

Aegis Capital was the sole book-running manager on the offering while Feltl and Co. acted as the co-manager.

The Rutherford, NJ-based cancer diagnostics firm went public last week, offering 600,000 shares of its stock at $10 per share. Cancer Genetics trades on the OTCQB Marketplace under ticker symbol "CGIX".

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.